Bryan Walker, MHS, PA-C

October 08, 2021

Advice and resources for colleagues, including community practitioners and neurologists, to encourage collaboration and best support for patients with multiple sclerosis (MS).

October 08, 2021

An optimistic look at the future management of multiple sclerosis (MS) based on newer treatment options and ongoing research in the field.

October 01, 2021

Recommendations surrounding the use of complementary and natural therapies to manage symptoms of multiple sclerosis (MS).

October 01, 2021

Best practices for establishing treatment plans for patients with relapse-remitting multiple sclerosis (RRMS) and making decisions to switch therapies based on inadequate treatment responses, relapse, or disease progression.

September 24, 2021

An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.

September 24, 2021

Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.

September 17, 2021

An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.

September 17, 2021

Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.

September 10, 2021

Bryan Walker, MHS, PA-C, describes the rationale for treating relapsing multiple sclerosis (MS) with sphingosine 1-phosphate (S1P1) receptor modulators and compares available options.

September 10, 2021

Best practices for treating patients with relapsing multiple sclerosis (MS) with cladribine, based on data revealed by clinical trials and experience in real-world practice.